Komipharm In Spotlight As It Files For Emergency Trials Against Coronavirus
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
You may also be interested in...
As South Korean companies jump into the development of vaccines and drugs for the coronavirus, they also call for stronger government support and increased collaboration between the state and private sectors.
EyeGene R&D head talks to Scrip at CPhI Korea about the development of its COVID-19 vaccine candidate EG-COVID, potential challenges in clinical trials and positioning and the over-riding importance of validating a viable mRNA platform.
EuBiologics CEO Yeong Ok Baik sat down with Scrip at CPhI Korea to talk about why he wants to develop vaccines for global public health needs and what plans are in store for its late-stage recombinant protein candidate for COVID-19.